Skip to main content
https://pbs.twimg.com/media/G6EwNi2WcAAfPyd.jpg
Metanalysis of 56 articles & 72,677 RA pts w/ a Dz duration of 9.7 yrs looked at biologic persistence. In csDMARD-IR, over 5 yrs TCZ (66%) & golimumab (62%) best. In bDMARD-IR, ABA (45%) & ETN (41%) best. Lower Rx survival predicted by steroids, hi Dz activity, & female https://t.co/tepL0A9Fwb
Dr. John Cush
Nov-18-2025
×